A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

TY - JOUR

T1 - A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

AU - Bond, David A.

AU - Huang, Ying

AU - Christian, Beth A.

AU - Jaglowski, Samantha

AU - Benson, Don

AU - Alinari, Lapo

AU - Baiocchi, Robert A.

AU - Cohen, Jonathon B.

AU - Blum, Kristie A.

AU - Maddocks, Kami J.

N1 - Funding Information: DB has consulted for Sea Gen and Kite/Gilead. BC has received research funding from Acerta, Celgene, Genentech, Triphase, MorphoSys, and Merck and has consulted for Verastem, Sea Gen, Genentech, and Astra Zeneca. SJ has received research funding from Gilead, Novartis, and Unum and has consulted for Bristol Myers Squibb, Gilead, and Novartis. JC has received research funding from Janssen, Novartis, TG Therapeutics, Astra Zeneca, Genentech, and Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, Astra Zeneca, Loxo, and Sea Gen. KM has received research funding from Novartis, Bristol Myers Squibb, and Pharmacyclics and has consulted for Morphosys, ADC Therapeutics, Astra Zeneca, Beigene, Celgene, Gilead, and Sea Gen. All other authors declare no competing interests.

PY - 2022

Y1 - 2022

UR - https://www.scopus.com/pages/publications/85124363293

U2 - 10.1080/10428194.2022.2034154

DO - 10.1080/10428194.2022.2034154

M3 - Letter

C2 - 35129029

AN - SCOPUS:85124363293

SN - 1042-8194

VL - 63

SP - 1750

EP - 1753

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -